Objective: Copy number variations (CNVs), a major cause of genetic hearing loss, most frequently involve the STRC gene, located on chr15q15.3 and causally related to autosomal recessive non-syndromic hearing loss (ARNSHL) at the DFNB16 locus. The interpretation of STRC sequence data can be challenging due to the existence of a virtually identical pseudogene, pSTRC, that promotes complex genomic rearrangements in this genomic region. Targeted genomic enrichment with massively parallel sequencing (TGE+MPS) has emerged as the preferred method by which to provide comprehensive genetic testing for hearing loss. We aimed to identify CNVs in the STRC region using established and validated bioinformatics methods. Methods: We used TGE+MPS to identify the genetic cause of hearing loss. The CNV results were confirmed with customized array comparative genomic hybridization (array CGH). Results: Three probands with progressive mild to moderate hearing loss were found among 40 subjects with ARNSHL to segregate homozygous STRC deletions and gene to pseudogene conversion. Array CGH showed that the deletions/ conversions span multiple genes outside of the exons captured by TGE+MPS. Conclusion: These data further validate the necessity to integrate the detection of both simple variant changes and complex genomic rearrangements in the clinical diagnosis of genetic hearing loss.
Introduction
Complex genomic alterations are an important cause of disease. While attention is most frequently focused on single nucleotide variations (SNVs), copy number variations (CNVs), traditionally considered the alteration through deletion, insertion, and/or duplication of more than ~1 kbp, are implicated in many different diseases and neurodevelopmental disorders. 1, 2 Included in this list is sensorineural hearing loss (SNHL), a disease phenotype in which CNVs play a major role. Using comprehensive genetic testing platforms, CNVs have been identified in about 20% of all deafness-causing genes and can be found in about 15% of patients who undergo genetic testing. 3 STRC is the deafness-causing gene most frequently associated with CNV events, with the CNV event most often leading to complete deletion of this gene. 3 These deletions have an estimated prevalence of 1% in deaf populations. 4 Defining the extent of a STRC CNV is challenging because the genomic region includes 4 genes, 3 of which have highly homologous pseudogenes. For example, the pseudo-STRC gene (pSTRC) has 98% homology to the functional STRC gene. Accurately assessing the rearrangement size in this region takes on added importance because when the neighboring CATSPER2 gene is included in the CNV and is also deleted, the phenotype becomes complex. 5 In addition to hearing loss, males have infertility secondary to altered sperm motility and therefore carry the diagnosis of deafness infertility syndrome (DIS). 6, 7 Female fertility is not affected.
In this study, we compare the results of TGE+MPS and high-resolution array comparative genomic hybridization (aCGH) to characterize CNVs involving the STRC gene in 3 Japanese families, segregating deafness at the DFNB16 locus.
Subjects and Methods
Families screened in this study were identified as part of a comprehensive genetic screen of 194 Japanese subjects (114 females) from unrelated and non-consanguineous families identified in 33 otolaryngology clinics in 28 prefectures across Japan. The complete details of this cohort have been previously reported. 8 For each proband, informed consent was obtained to participate in this study, which was approved by the human subjects ethical committee associated with each clinic. Clinical information and blood samples were obtained for each proband and for all consenting affected and unaffected relatives.
Targeted Genomic Enrichment and Massively Parallel Sequencing
We sequenced all exons of all known non-syndromic hearing loss genes and non-syndromic hearing loss mimic genes as described previously. The TGE and library preparation were completed using a modified solution-phase protocol based on the Agilent SureSelect target enrichment system. Prior to library preparation, genomic DNA quality was assessed by gel electrophoresis and Nanodrop 1000 spectrophotometer (Thermo Scientific, Inc, Waltham, Massachusetts, USA) (260/280 ration = 1.8-2.2) and quantitated using a Qubit 2.0 fluorometer (Life Technologies, Carlsbad, California, USA). Three μg of gDNA was randomly fragmented to an average size of 250 bp by sonication with a Covaris acoustic solubilizer (Covaris Inc, Woburn, Massachusetts, USA), fragment ends were repaired, A-tails were added, and sequencing adaptors were ligated prior to the first amplification. Solid phase reverse immobilization purification was performed between each enzymatic reaction. Hybridization and capture with RNA baits was followed by a second amplification before pooling for sequencing. In all cases, the smallest number of amplifications possible was used: typically 8 cycles for the pre-hybridization PCR (range, 8-10 cycles using NEB Phusion HF Master Mix) and 14 cycles for the post-hybridization PCR (range, 12-16 cycles using Agilent Herculase II Fusion DNA Polymerase). All samples were barcoded and multiplexed before sequencing. We performed sequencing using the Illumina HiSeq system in pools of 48 samples per lane using 100-bp pairedend reads.
Copy Number Analysis on MPS Data
We completed read mapping with BWA and realignment with GATK, using the indexed BAM file to call variants and generate a pileup using samtools, retaining only the position and depth information. The CNV calling was completed using a custom R script, a previously published tool. 9 This method normalizes read-depth data by sample batch using a sliding-window approach. We used the 2011-07-01 version of the tool with default settings. All CNV calls were curated through manual inspection.
Array CGH
We designed a custom aCGH platform using the Agilent SureDesign website to select for inclusion of 86 known deaf genes, with probes covering these genomic regions at 150 to 200 bp intervals on the Agilent 8x60K platform (Agilent Technologies, Santa Clara, California, USA). The aCGH was completed using the same gDNA samples as for TGE+MPS. Ten ul of gDNA solution (0.5 ug of DNA) was fragmented, labeled with cyanine-3 (reference DNA) or cyanine-5 (subjects), and hybridized. Scanning of the array was completed following the manufacturer's recommended protocols; scanned aCGH data were analyzed using CytoGenomics software v3.0.6.6 (Agilent Technologies, Santa Clara, California, USA).
Results

Case Details
Case 1: Patient No. 167. This 12-year-old male was identified with hearing loss at a school check-up. His brother was also having hearing loss. Newborn hearing screening data were not available, so the exact age of onset was not known. He did not have any complaints of vertigo or tinnitus. Both parents had normal hearing (Figure 1 ).
Case 2: Patient
No. 260. This 12-year-old male was first noted to have hearing loss at a school check-up. Although he was diagnosed with mild hearing loss, he was not aware of any difficulty hearing. His brother (patient No. 261) had a similar mild sloping hearing loss (Figure 1 ).
Case 3: Patient
No. 4590. This 26-year-old female noticed hearing loss in early childhood. Serial audiological assessments showed a slow deterioration in hearing. She had no episodes of vertigo; however, she did complain of tinnitus. Her elder brother (patient No. 4591) had more severely progressive hearing loss (Figure 1 ).
CNVs in the STRC Genomic Region
Two probands were homozygous for a deletion of STRC (prevalence among deaf subjects in this study, 7.5%). We also identified 1 subject who was heterozygous for a STRC gene deletion and 1 with a heterozygous gene duplication of STRC.
The CNV analysis derived from TGE+MPS identified a homozygous deletion encompassing STRC and CATSPER2 genes in 2 probands (No. 167 and No. 4590) and a biallelic partial STRC gene to pseudogene conversion in one proband (No. 260) ( Figure 2 ). As shown in Figure 3 , array CGH confirmed a homozygous deletion of STRC through CATSPER2 in cases 1 and 3. Segregation analysis confirmed a heterozygous deletion in the parental samples of case 3, with no obvious changes in the pSTRC region. Case 2 also carried a homozygous deletion of the STRC to CATSPER2 region, with at least 2 or more copies of the pSTRC region predicted (indicated by blue dots). Parental samples of Case 2 showed only heterozygous deletion of the STRC to CATSPER2 region.
Discussion
We identified 3 patients with ARNSHL caused by CNVs in STRC in a Japanese hearing loss population for an estimated prevalence of 7.5% (3/40 ARNSHL probands). This figure is similar to that reported by Vona et al, 10 who found 6 of 94 SNHL subjects (6.4%) with homozygous or compound heterozygous STRC deletions as a cause of hearing loss using whole-genome aCGH. The carrier frequency of STRC deletions has been estimated at 1.1% to 2.5%. 4, 11 We analyzed only a limited number of 40 ARNSHL samples, thus further study is necessary to clarify the prevalence of CNV in the STRC.
The CNVs are found in 13% of the human genome and may be underestimated as a cause of SNHL to difficulties and limitations in their detection. 13 Although several methods including multiplex ligation-dependent probe amplification (MLPA), single nucleotide polymorphism (SNP) arrays, and aCGH can be used to identify CNVs, these analyses are not routinely included in genetic testing for SNHL. Fortunately, with the implementation of TGE+MPS in the comprehensive evaluation of SNHL, detection of CNVs can be integrated into the bioinformatics analysis. Furthermore, targeted genomic regions can be expanded with additional probes to improve CNV identification when the gene locations or positions in which CNVs commonly occurred were well established.
Using a customized aCGH pipeline, we confirm the validity of this approach for the detection of STRCassociated CNVs. There was high concordance between the MPS CNV analysis, and the aCGH results provided more data throughout the STRC genomic region. This result is important as CNVs in STRC are a common cause of mild to moderate ARNSHL. 3, 14, 15 In summary, we propose that genomic alterations including CNVs should be considered as a major cause of SNHL and that genetic testing must integrate SNV and CNV identification.
